These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25522326)

  • 1. Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1.
    McCoy LE; Rutten L; Frampton D; Anderson I; Granger L; Bashford-Rogers R; Dekkers G; Strokappe NM; Seaman MS; Koh W; Grippo V; Kliche A; Verrips T; Kellam P; Fassati A; Weiss RA
    PLoS Pathog; 2014 Dec; 10(12):e1004552. PubMed ID: 25522326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.
    Strokappe N; Szynol A; Aasa-Chapman M; Gorlani A; Forsman Quigley A; Hulsik DL; Chen L; Weiss R; de Haard H; Verrips T
    PLoS One; 2012; 7(3):e33298. PubMed ID: 22438910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.
    Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P
    J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization.
    McCoy LE; Quigley AF; Strokappe NM; Bulmer-Thomas B; Seaman MS; Mortier D; Rutten L; Chander N; Edwards CJ; Ketteler R; Davis D; Verrips T; Weiss RA
    J Exp Med; 2012 Jun; 209(6):1091-103. PubMed ID: 22641382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrapotent Broadly Neutralizing Human-llama Bispecific Antibodies against HIV-1.
    Xu J; Zhou T; McKee K; Zhang B; Liu C; Nazzari AF; Pegu A; Shen CH; Becker JE; Bender MF; Chan P; Changela A; Chaudhary R; Chen X; Einav T; Kwon YD; Lin BC; Louder MK; Merriam JS; Morano NC; O'Dell S; Olia AS; Rawi R; Roark RS; Stephens T; Teng IT; Tourtellott-Fogt E; Wang S; Yang ES; Shapiro L; Tsybovsky Y; Doria-Rose NA; Casellas R; Kwong PD
    Adv Sci (Weinh); 2024 Jul; 11(26):e2309268. PubMed ID: 38704686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.
    Forsman A; Beirnaert E; Aasa-Chapman MM; Hoorelbeke B; Hijazi K; Koh W; Tack V; Szynol A; Kelly C; McKnight A; Verrips T; de Haard H; Weiss RA
    J Virol; 2008 Dec; 82(24):12069-81. PubMed ID: 18842738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
    McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
    J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Easterhoff D; Bradley T; Luo K; Williams WB; Liao HX; Moody MA; Phad GE; Vázquez Bernat N; Melillo B; Santra S; Smith AB; Karlsson Hedestam GB; Haynes B; Sodroski J
    J Virol; 2016 May; 90(10):5031-5046. PubMed ID: 26962221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
    Liao HX; Lynch R; Zhou T; Gao F; Alam SM; Boyd SD; Fire AZ; Roskin KM; Schramm CA; Zhang Z; Zhu J; Shapiro L; ; Mullikin JC; Gnanakaran S; Hraber P; Wiehe K; Kelsoe G; Yang G; Xia SM; Montefiori DC; Parks R; Lloyd KE; Scearce RM; Soderberg KA; Cohen M; Kamanga G; Louder MK; Tran LM; Chen Y; Cai F; Chen S; Moquin S; Du X; Joyce MG; Srivatsan S; Zhang B; Zheng A; Shaw GM; Hahn BH; Kepler TB; Korber BT; Kwong PD; Mascola JR; Haynes BF
    Nature; 2013 Apr; 496(7446):469-76. PubMed ID: 23552890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
    Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
    Bonsignori M; Montefiori DC; Wu X; Chen X; Hwang KK; Tsao CY; Kozink DM; Parks RJ; Tomaras GD; Crump JA; Kapiga SH; Sam NE; Kwong PD; Kepler TB; Liao HX; Mascola JR; Haynes BF
    J Virol; 2012 Apr; 86(8):4688-92. PubMed ID: 22301150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice.
    Kosztyu P; Kuchar M; Cerny J; Barkocziova L; Maly M; Petrokova H; Czernekova L; Liskova V; Raskova Kafkova L; Knotigova P; Masek J; Turanek J; Maly P; Raska M
    EBioMedicine; 2019 Sep; 47():247-256. PubMed ID: 31544770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.
    Dai K; He L; Khan SN; O'Dell S; McKee K; Tran K; Li Y; Sundling C; Morris CD; Mascola JR; Karlsson Hedestam GB; Wyatt RT; Zhu J
    mBio; 2015 Nov; 6(6):e01375-15. PubMed ID: 26530382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
    Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
    PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.